New York, NY, United States of America

Richard L Weinshank

This inventor holds 56 USPTO granted patents and 1 EPO patent, primarily in Neuropeptide Receptors (CPC class 4353). Top assignees: Synaptic Pharmaceutical Corporation, H. Lundbeck A/s, Neurogenetic Corporation. Active years: 1991-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard L Weinshank. Retrieved from https://idiyas.com/inventor/richard-l-weinshank

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 92.9


Average Co-Inventor Count = 3.3

ph-index = 10

Forward Citations = 346(Granted Patents)

Forward Citations (Not Self Cited) = 284(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • New York, NY (US) (1991 - 2005)
  • Teaneck, NJ (US) (1999 - 2006)

Company Filing History:


Years Active: 1991-2006

Loading Chart...
Loading Chart...
Areas of Expertise:
Galanin Receptor
Dopamine Receptor
Neuropeptide Y
Serotonin Receptor
Y2 Receptor
Y4 Receptor
5-HT1D
5-HT4B
Feeding Behavior
Compound Identification
GABA Transporter
Migraine Treatment
56 patents (USPTO):Explore Patents

Title: Richard L Weinshank: A Proficient Innovator in Galanin Receptors

Introduction:

Richard L Weinshank, an inventive mind in New York, NY, has made significant contributions in the field of galanin receptors. With a total of 56 patents to his name, Weinshank's dedication and expertise have opened new avenues in the understanding and utilization of galanin receptor proteins. In this article, we will explore his latest patents, career highlights, and collaborations that have marked his journey as an accomplished innovator.

Latest Patents:

Weinshank's recent patents highlight his pioneering work in isolating nucleic acids encoding mammalian galanin receptors, along with a range of related applications. These patents include the following inventions:

1. Uses of galanin GALR2 receptors:

This invention encompasses isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acids, cells containing such vectors, antibodies targeting mammalian galanin receptors, nucleic acid probes for detection, antisense oligonucleotides, and nonhuman transgenic animals expressing DNA encoding normal or mutant galanin receptors. It also encompasses methods for determining the binding of compounds to mammalian galanin receptors.

2. Method of preparing GALR2 receptors composition:

Similar to the first patent, this invention focuses on isolated nucleic acids encoding mammalian galanin receptors, isolated receptor proteins, vectors containing these nucleic acids, cells carrying such vectors, antibodies directed towards mammalian galanin receptors, nucleic acid probes for detection, antisense oligonucleotides, and nonhuman transgenic animals expressing DNA encoding normal or mutant galanin receptors. It also involves methods for evaluating the binding affinity of compounds to mammalian galanin receptors.

Career Highlights:

Weinshank's career has been marked by his invaluable contributions to advancing the field of galanin receptors. Notably, he has worked with renowned companies such as Synaptic Pharmaceutical Corporation and H. Lundbeck A/S. These collaborations have allowed him to leverage his inventive skills and work alongside industry experts to develop breakthrough solutions.

Collaborations:

Throughout his career, Richard L Weinshank has collaborated with accomplished professionals in the field, including Theresa A Branchek and Paul R Hartig. Their combined expertise and dedication have propelled the development and application of galanin receptor technologies, pushing the boundaries of scientific understanding and potential therapeutic interventions.

Conclusion:

Richard L Weinshank's impressive portfolio of patents demonstrates his exceptional aptitude for innovation in galanin receptors. His patents have paved the way for new discoveries, promising novel therapeutic prospects and facilitating further research in this field. Through his collaborations and industry experience, Weinshank has reinforced his standing as a driving force behind advancements in the understanding and utilization of galanin receptors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…